var data={"title":"Canakinumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Canakinumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388450?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=canakinumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Canakinumab: Patient drug information&quot;</a> and <a href=\"topic.htm?path=canakinumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Canakinumab: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874024\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ilaris;</li>\n      <li>Ilaris (150mg Delivered) [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14946785\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ilaris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7879808\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Interleukin-1 Beta Inhibitor;</li>\n      <li>\n        Interleukin-1 Inhibitor;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883738\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryopyrin-associated periodic syndromes (CAPS):</b> SubQ: 150 mg (&gt;40 kg) or 2 mg/kg (15 to 40 kg) every 8 weeks; in clinical trials, dosage adjustments up to 600 mg (&gt;40 kg) or 8 mg/kg (&le;40 kg) and/or increased dosing frequency were allowed for residual symptoms (Kuemmerle-Deschner 2011). For inadequate response, a dose titration schedule of 150 mg or 2 mg/kg every 7 days up to a maximum dose of 600 mg or 8 mg/kg (15 to 40 kg) has been recommended (Ilaris Canadian product labeling 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial Mediterranean Fever (FMF), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): </b>SubQ: 150 mg (&gt;40 kg) or 2 mg/kg (&le;40 kg) every 4 weeks; may increase to 300 mg (&gt;40 kg) or 4 mg/kg (&le;40 kg) every 4 weeks if response is not adequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gout, treatment of acute flares (when conventional therapy is ineffective, contraindicated, or not tolerated) (off-label use): </b>SubQ: 150 mg as a single dose (Schlesinger 2012). Additional data may be necessary to further define the role of canakinumab in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883737\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=canakinumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Canakinumab: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryopyrin-associated periodic syndromes (CAPS):</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 to 40 kg: 2 mg/kg every 8 weeks; may increase to 3 mg/kg if response inadequate; in clinical trials, dosage adjustments up to 8 mg/kg and/or increased dosing frequency were allowed for residual symptoms (Kuemmerle-Deschner 2011). For inadequate response, a dose titration schedule of 2 mg/kg every 7 days up to a maximum dose of 8mg/kg has been recommended (Ilaris Canadian product labeling 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial Mediterranean Fever (FMF), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): </b>SubQ: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic juvenile idiopathic arthritis (SJIA):</b> SubQ: Children &ge;2 years and &ge;7.5 kg and Adolescents: 4 mg/kg every 4 weeks (maximum: 300 mg per dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883739\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965455\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965456\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9512584\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ilaris: 150 mg/mL (1 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ilaris (150mg Delivered): 180 mg (1 ea [DSC]) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7884596\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965457\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ilaris: 150 mg [contains polysorbate 80, sucrose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20403141\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM352352.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5W92ivjwVDG4ZXa+dFfFcX3Q==&amp;TOPIC_ID=8906\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM352352.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883740\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: For subcutaneous injection only. Do not shake solution. Do not inject into scar tissue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7879810\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodic fever syndromes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryopyrin-associated periodic syndromes:</b> Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 4 years and older, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). <b>Note:</b> Has also been studied in Neonatal-onset multisystem inflammatory disease (Ilaris Canadian product labeling 2017; Sibley 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Familial Mediterranean fever:</b> Treatment of familial Mediterranean fever in adult and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD): </b>Treatment of hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tumor necrosis factor (TNF) receptor associated periodic syndrome:</b> Treatment of TNF receptor associated periodic syndrome (TRAPS) in adult and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic juvenile idiopathic arthritis:</b> Treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years and older.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50782590\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Gout, treatment of acute flares (when conventional therapy is ineffective, contraindicated, or not tolerated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883696\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (14%), vertigo (9% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (20%), upper abdominal pain (7% to 16%), nausea (14%), gastroenteritis (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (30% to 54%; serious infection: 2% to 5%), influenza (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular and skeletal: Musculoskeletal pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (11% to 34%), rhinitis (5% to 17%), bronchitis (11%), pharyngitis (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum calcium (8% [Lachmann 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Proteinuria (8% [Lachmann 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased white blood cell count (10%), eosinophilia (7% [Lachmann 2009]), decreased neutrophils (transient: &le;7%), decreased platelet count (mild and transient: &le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (7% [Lachmann 2009]), increased serum AST (&le;4%), increased serum ALT (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (non-neutralizing: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Decreased creatinine clearance (8% [Lachmann 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883693\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to canakinumab or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Active, severe infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883694\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: A decrease in WBC, neutrophils, and platelets was observed in clinical trials; some changes were transient and/or mild (eg, thrombocytopenia). One case of neutropenia (ANC &lt;1,500/mm<sup>3</sup>) was reported; monitor blood counts as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (excluding anaphylactic reactions) have been reported with use; symptoms may be similar to those that are disease related.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Caution should be exercised when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with latent or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued. Therapy should not be initiated in patients with active or chronic infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macrophage activation syndrome (MAS): MAS may develop in patients with SJIA and should be treated aggressively. Infection or worsening SJIA may be triggers for MAS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Use may impair defenses against malignancies; impact on the development and course of malignancies is not fully defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Avoid use in patients with active tuberculosis (TB). Patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Treat latent TB infections prior to initiating canakinumab therapy. During and following treatment, monitor for signs/symptoms of active TB.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: All patients should be brought up to date with all immunizations including pneumococcal and influenza vaccines before initiating therapy. Live vaccines should not be given concurrently; no data available on either the efficacy or on the risks concerning secondary transmission of infection by live vaccines in patients receiving therapy. Administration of inactivated (killed) vaccines while on therapy may not be effective.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298949\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7899286\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8906&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interleukin-1 Inhibitors: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interleukin-1 Receptor Antagonist: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883689\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Canakinumab is a recombinant IgG monoclonal antibody; IgG is known to cross the placenta in a linear fashion as pregnancy progresses; potential fetal exposure is likely to be greater during the second and third trimesters.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20607144\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if canakinumab is present in breast milk. However, canakinumab is a recombinant IgG monoclonal antibody; human IgG is present in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883742\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, C-reactive protein (CRP), serum amyloid A protein A (SAA); signs of infection; latent TB screening (prior to initiating therapy).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Eye examinations for patients with CAPS (Caorsi 2013) and symptoms of disease for patients with CAPS or SJIA (Caorsi 2013; Lachmann 2009; Ruperto 2012) were also monitored in clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883719\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Canakinumab reduces inflammation by binding to interleukin-1 beta (IL-1beta) (no binding to IL-1 alpha  or IL-1 receptor antagonist [IL-1ra]) and preventing interaction with cell surface receptors. Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates IL-1beta activation. Deficiency of cryopyrin results in excessive inflammation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883721\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Maximum effect: Within 8 days CRP and serum amyloid normalization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Children: 0.097 L/kg (3.2 L in 33 kg); Adults: CAPS: 0.086 L/kg (6 L in 70 kg); FMF, HIDS/MKD, TRAPS: 0.09 L/kg (6.34 L in 70 kg).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Binds to serum IL-1 beta</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Subcutaneous: 66%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children &ge;4 years: 22.9 to 25.7 days; Adults: 26 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Children &ge;4 years: 2 to 7 days; Adults: ~7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: Varies according to body weight:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &le;40 kg: SJIA: 0.11 L/day in 33 kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;40 kg and Adults: CAPS: 0.174 L/day in 70 kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children, Adolescents, and Adults: FMF, HIDS/MKD, TRAPS: 0.17 L/day in 70 kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322118\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ilaris Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $19,266.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707699\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ilaris (AE, AR, AT, BE, BR, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, IE, IL, JP, KR, KW, LT, LU, MT, NL, NO, NZ, PH, PL, PT, QA, SA, SE, SG, SI, SK, TR, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caorsi R, Lepore L, Zulian F, et al, &quot;The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome is Driven By the Phenotype Severity Rather Than the Age,&quot; <i>Arthritis Res Ther</i>, 2013, 15(1):R33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/23442610/pubmed\" target=\"_blank\" id=\"23442610\">23442610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilaris (canakinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilaris (canakinumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kon&eacute;-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al, &quot;Canakinumab in CAPS Study Group. Sustained Remission of Symptoms and Improved Health-Related Quality of Life in Patients With Cryopyrin-Associated Periodic Syndrome Treated With Canakinumab: Results of a Double-Blind Placebo-Controlled Randomized Withdrawal Study,&quot; <i>Arthritis Res Ther</i>, 2011, 13(6):R202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/22152723/pubmed\" target=\"_blank\" id=\"22152723\">22152723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al, &quot;Two-Year Results From an Open-Label, Multicentre, Phase III Study Evaluating the Safety and Efficacy of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Across Different Severity Phenotypes,&quot; <i>Ann Rheum Dis</i>, 2011, 70(12):2095-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/21859692/pubmed\" target=\"_blank\" id=\"21859692\">21859692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, &ldquo;Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome,&rdquo; <i>N Engl J Med</i>, 2009, 360(23):2416-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/19494217/pubmed\" target=\"_blank\" id=\"19494217\">19494217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NCT 00685373, &ldquo;Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease&rdquo;, Unpublished data. Available at <a href=\"http://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;amp;rank=1\" target=\"_blank\">http://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;rank=1</a>. Date Accessed: October 29, 2011</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/27457514/pubmed\" target=\"_blank\" id=\"27457514\">27457514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Brunner HI, Quartier P, et al, &quot;Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis,&quot; <i>N Engl J Med</i>, 2012, 367(25):2396-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/23252526/pubmed\" target=\"_blank\" id=\"23252526\">23252526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22586173\"></a>Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. <i>Ann Rheum Dis</i>. 2012;71(11):1839-1848. doi: 10.1136/annrheumdis-2011-200908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/22586173/pubmed\" target=\"_blank\" id=\"22586173\">22586173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sibley CH, Chioato A, Felix S, et al. A 24 month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. <i>Ann Rheum Dis</i>. 2015;74(9):1714-1719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/24906637/pubmed\" target=\"_blank\" id=\"24906637\">24906637</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8906 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7874024\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14946785\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7879808\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7883738\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7883737\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7883739\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14965455\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14965456\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9512584\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7884596\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F14965457\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F20403141\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7883740\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7879810\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50782590\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7883696\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7883693\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7883694\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298949\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7899286\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7883689\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20607144\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7883742\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7883719\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7883721\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322118\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707699\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8906|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=canakinumab-patient-drug-information\" class=\"drug drug_patient\">Canakinumab: Patient drug information</a></li><li><a href=\"topic.htm?path=canakinumab-pediatric-drug-information\" class=\"drug drug_pediatric\">Canakinumab: Pediatric drug information</a></li></ul></div></div>","javascript":null}